Is there a procoagulant state long-term after lung transplantation? A prospective study
Por:
Saez-Gimenez, B, Clofent, D, Meseguer, M, Masgoret, C, Monforte, V, Berastegui, C, Revilla-Lopez, E, Barrecheguren, M, Arjona-Peris, M, Ruiz, V, Ramon, M, Gomez-Olles, S, Santamaria, A and Roman, A
Publicada:
1 sep 2021
Categoría:
Pulmonary and respiratory medicine
Resumen:
Background: Venous thromboembolism (VTE) is a major complication after lung transplantation (LT). However, its pathophysiology remains unknown, and coagulation profiles have yet to be described.
Objective: The aim of this study was to longitudinally assess coagulation status after LT.
Methods: We performed a prospective study and described the coagulation profiles of 48 patients at 5 different time-points: before LT and at 24-72 h, 2 weeks, 4 months, and 1 year after LT. Results: At baseline, almost all analyzed coagulation factors were within the normal range, except for FVIII, which was above the normal range. Von Willebrand factor (vWF) and FVIII were increased after LT and remained high at 1 year after transplantation. The cumulative incidence of VTE was 22.9%. Patients who developed VTE had higher FVIII activity 2 weeks after LT.
Conclusions: This is the first study to describe coagulation profiles up to 1 year after LT. We show that most markers of a procoagulant state normalize at 2 weeks after LT, but that values of FVIII and vWF remain abnormal at 1 year. This problem has received little attention in the literature. Larger studies are necessary to confirm the results and to design appropriate prophylactic strategies.
Filiaciones:
Saez-Gimenez, B:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Univ Autonoma Barcelona, Dept Cell Biol Physiol & Immunol, Barcelona, Spain
Clofent, D:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Meseguer, M:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Masgoret, C:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
Monforte, V:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
Berastegui, C:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Revilla-Lopez, E:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Barrecheguren, M:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Arjona-Peris, M:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Ruiz, V:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Ramon, M:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
Gomez-Olles, S:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
:
Hosp Univ Vall DHebron, Hemostasis & Thrombosis Unit, Dept Hematol, Barcelona, Spain
Roman, A:
Univ Autonoma Barcelona, Pulmonol Serv, Lung Transplant Program, Hosp Univ Vall DHebron, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
|